Insilico Medicine Releases Pandomics, AI-powered Platform for Novel Therapeutic Target Discovery

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

September 23, 2020

Insilico Medicine announces the official release of Pandomics, a part of the Pharma.ai AI platform designed to empower pharmaceutical target and drug discovery pipelines. Research biologists and clinicians can use Pandomics to perform OMICS data analytics and interpretation without requiring any prior knowledge of computational biology or bioinformatics. Additionally, drug target identification and biomarker development specialists can generate powerful hypotheses and assess repositioning strategies by harnessing the power of Artificial Intelligence (AI).

Insilico Medicine started working on an engine for target identification back in 2014. Since then, the technology has been validated through several successful partnering initiatives with pharmaceutical companies and research organizations as well as through Insilico Medicine’s own internal drug development programs.

Pandomics aims to be the go-to platform for all biologists and clinicians, working with various OMICS datasets, and to quickly analyze, interpret, and visualize data effectively in order to classify patient cohorts more accurately.

“At Insilico, we have developed a platform that hands the power of bioinformatics over to the researcher’s hands. Biologists, clinicians, and therapeutic target specialists will gain a wide range of novel visual ways to interpret biological data. When designing the tool, we focused on storytelling in data analysis and providing guidance for each step,” said Alexey Dubovenko, Product Director for Pandomics at Insilico Medicine.

“We recently used parts of the Pandomics platform in combination with Chemistry42, our generative chemistry platform, and inClinico, our clinical trials prediction platform, to demonstrate that we can go from the nomination of disease of interest to novel disease targets to compounds that are ready to enter IND-enabling studies in record time. We also collaborated with dozens of key opinion leaders in different disease areas to complete experimental validation of Pandomics. We are very happy to put this system into the hands of research scientists, drug discovery and development experts, and medical doctors interested in research and academic publishing,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.